United Therapeutics Corporation
UTHRUnited Therapeutics Corporation's price has outrun its earnings. +76.3% in a year against EPS +13.1% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +76.3% in a year while annual EPS moved +13.1% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (36 weeks in) while the P/E sits at the 91st percentile of its own 4-year range. Underneath, the last four quarters read deteriorating — profit −15.6% year on year, and 110% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
United Therapeutics Corporation trades at $519, in a confirmed uptrend and 36 weeks into that stage. That is +0.7% against its own 200-day average. It sits at 75% of a 52-week range of $305 to $588. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (9 weeks and counting).
Today the stock is in a confirmed uptrend — week 36 of stage 2. At $519 it trades +0.7% versus its 200-day average and sits at 75% of its 52-week range ($305–$588).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +367% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (9 weeks and counting; last ahead the week of 2026-06-05) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
United Therapeutics Corporation trades at 19.2× P/E, at the pricey end of its own range (91st percentile). Its long-run median P/E is 15.2×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 19.2× is at the pricey end of its own range (91st percentile), against a long-run median of 15.2× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +13.1% against a +76.3% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +30.0%/yr price move, ~+15.3%/yr came from earnings growth and ~+14.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
United Therapeutics Corporation reads as topping out on its fundamental arc. Topping out — revenue and EPS growth have decelerated hard (revenue growth +24.4% at its peak → +6.0% latest) while ROCE still reads 21.9%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +10.4% | +17.9% | — | — |
| Profit | +10.8% | +22.1% | — | — |
| EPS | +13.1% | +22.9% | — | — |
| Stock price | +76.3% | +30.0% | +19.5% | +15.3% |
4-Factor Sector Score
42.7/100 — rank 18 of 28 in Drug Manufacturers - Specialty & Generic · 81% evidence confidence
United Therapeutics Corporation scores 42.7 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 18. Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
The four contributions add to the total exactly: 15 + 16.5 + 6.3 + 4.9 = 42.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
United Therapeutics Corporation reported $0.8 B of revenue in the Mar 26 quarter, −1.3% year on year. Over 4 years it has compounded at 17.1% a year. The last full year, FY25, came in at $3.2 B. The last four reported quarters add to $3.2 B.
FY25 revenue came in at $3.2 B (+10.4% on the year), capping 4 years at 17.1% compound. The latest quarter (Mar 26) printed $0.8 B, −1.3% year on year.
Pace check: the last four quarters averaged +6.2% growth against the decade's 17.1% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +6.0% over the last 4 quarters against +12.6%/yr over the last 8 — rolling over; TTM profit +5.8% vs +9.9%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
United Therapeutics Corporation's operating margin is 42.3% in the Mar 26 quarter, −5.8 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 33.1% to 50.6%. The current quarter sits inside that band.
The latest quarter's operating margin is 42.3%, −5.8 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 33.1%–50.6%.
🚨 Why the margin moved: operating margin went −5.8 pp year on year while gross margin went −5.3 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
United Therapeutics Corporation earned $0.3 B of net profit in the Mar 26 quarter, −15.6% year on year. Full-year FY25 profit was $1.3 B. The 4-year compound rate is 29.0%. That is 34.6% of the quarter's revenue. The same quarter a year earlier earned $0.3 B.
Mar 26 profit was $0.3 B, −15.6% year on year. On the full year, FY25 printed $1.3 B (+10.8%), and the 4-year compound rate is 29.0%.
🚨 Why profit moved: revenue contributed −1.3% and the margin −5.8 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +6.2% vs revenue +6.2%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 110% of United Therapeutics Corporation's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $1.6 B of operating cash against $1.3 B of profit. After $0.5 B of capital spending, $1.0 B was left as free cash.
FY25: operating cash of $1.6 B against reported profit of $1.3 B, leaving free cash of $1.0 B after $0.5 B of capital spending. Across the last 3 fiscal years the conversion rate is 110% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
United Therapeutics Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $1.0 B over the last 3 years. Averaged over those years that is 10.5% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $1.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
United Therapeutics Corporation earns a ROE of 19% in FY25. That is up from a trough of 12% in FY21. Return on invested capital clears the cost of that capital by +22.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 41.8% net margin on 0.40× asset turns.
FY25 ROE is 19%, recovered from a FY21 trough of 12% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 41.8% net margin × 0.40× asset turns × 1.11× balance-sheet leverage ≈ 18.6% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 29.4% − 7.4% = a +22.0 pp spread. The 7.4% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend
United Therapeutics Corporation pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
United Therapeutics Corporation does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
United Therapeutics Corporation carries total debt of $0.0 B against shareholder equity of $5.9 B as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.20 in FY21 to 0.00 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of $0.0 B against shareholder equity of $5.9 B — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.20 (FY21) to 0.00 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
5.4% of United Therapeutics Corporation's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 3.8 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 5.4% of the float is sold short, and at typical trading volumes it would take about 3.8 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
United Therapeutics Corporation: the Z-score reads 16.45. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 16.45 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 16.45.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Liquidia CorporationLQDA | 72.3/100Favorable setup64% evidence | LEADER | 25.7/35 Revenue 100% · PAT — · OPM change 1181.7 pp 62% evidence | 18.0/25 ROCE 29.4% · OPM 46.3% 76% evidence | 8.6/20 P/E 269.6× · PEG — 15% evidence | 20.0/20 RS sector 86.6% · RS bench 89.6% · 1Y 332.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 25.7 + 18 + 8.6 + 20 = 72.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Indivior Pharmaceuticals, Inc.INDV | 63.8/100Mixed-positive evidence64% evidence | FADING | 24.0/35 Revenue 10.3% · PAT — · OPM change 18.4 pp 62% evidence | 21.0/25 ROCE 34.8% · OPM 43.2% 76% evidence | 11.4/20 P/E 3.1× · PEG — 15% evidence | 7.4/20 RS sector -1.2% · RS bench 0.8% · 1Y 65.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 21 + 11.4 + 7.4 = 63.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Amneal Pharmaceuticals, Inc.AMRX | 60.6/100Thin evidence · provisional58% evidence | BREAKING OUT | 19.6/35 Revenue — · PAT — · OPM change 5.2 pp 45% evidence | 13.3/25 ROCE 5% · OPM 19.6% 76% evidence | 9.8/20 P/E 35.3× · PEG — 15% evidence | 17.9/20 RS sector 26.4% · RS bench 28.8% · 1Y 116.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 13.3 + 9.8 + 17.9 = 60.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Kiniksa Pharmaceuticals International, plcKNSA | 59.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 19.3/35 Revenue — · PAT — · OPM change 4.1 pp 45% evidence | 12.0/25 ROCE 4.3% · OPM 13.7% 76% evidence | 9.1/20 P/E 101.5× · PEG — 15% evidence | 18.8/20 RS sector 45.1% · RS bench 47.9% · 1Y 136.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 12 + 9.1 + 18.8 = 59.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Lantheus Holdings, Inc.LNTH | 58.0/100Mixed-positive evidence81% evidence | FADING | 13.6/35 Revenue 0.6% · PAT 9.8% · OPM change -5.8 pp 83% evidence | 14.1/25 ROCE 4.3% · OPM 21.6% 76% evidence | 14.3/20 P/E 18.3× · PEG 1.02 65% evidence | 16.0/20 RS sector 20% · RS bench 22.2% · 1Y 76.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 14.1 + 14.3 + 16 = 58 · Decision use: Price leads the evidence: RS versus the benchmark is 22.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6Neurocrine Biosciences, Inc.NBIX | 56.7/100Thin evidence · provisional58% evidence | FADING | 19.5/35 Revenue — · PAT — · OPM change 19.6 pp 45% evidence | 14.0/25 ROCE 3.9% · OPM 23.7% 76% evidence | 10.0/20 P/E 24.7× · PEG — 15% evidence | 13.2/20 RS sector 0.5% · RS bench 2.9% · 1Y 32.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 14 + 10 + 13.2 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Phibro Animal Health CorporationPAHC | 55.9/100Mixed-positive evidence75% evidence | ASLEEP | 25.5/35 Revenue 26.1% · PAT 100% · OPM change 2 pp 83% evidence | 13.3/25 ROCE 4% · OPM 11.6% 76% evidence | 12.1/20 P/E 23.7× · PEG 1.31 65% evidence | 5.0/20 RS sector -22.4% · RS bench -20.8% · 1Y 30.2%0 of 12 weeks ahead 70% evidence |
| Exact sum: 25.5 + 13.3 + 12.1 + 5 = 55.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -22.4% and the one-year return is 30.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 8Xeris Biopharma Holdings, Inc.XERS | 53.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 24.5/35 Revenue 41.9% · PAT — · OPM change 14.6 pp 62% evidence | 8.8/25 ROCE 3.2% · OPM 9.5% 76% evidence | 9.3/20 P/E 96.7× · PEG — 15% evidence | 11.1/20 RS sector -0.7% · RS bench 1.7% · 1Y 19.7%9 of 12 weeks ahead 70% evidence |
| Exact sum: 24.5 + 8.8 + 9.3 + 11.1 = 53.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Haleon plcHLN | 52.6/100Thin evidence · provisional56% evidence | TURNING | 20.2/35 Revenue — · PAT — · OPM change 9.1 pp 39% evidence | 13.3/25 ROCE 2.2% · OPM 21.8% 76% evidence | 10.8/20 P/E 19.3× · PEG — 15% evidence | 8.3/20 RS sector -11.9% · RS bench -10% · 1Y 2.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.2 + 13.3 + 10.8 + 8.3 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Viatris Inc.VTRS | 51.2/100Mixed-positive evidence64% evidence | FADING | 21.8/35 Revenue 1.6% · PAT — · OPM change 86.3 pp 62% evidence | 7.7/25 ROCE -0.3% · OPM -2.3% 76% evidence | 8.7/20 P/E 216.6× · PEG — 15% evidence | 13.0/20 RS sector 17.5% · RS bench 19.7% · 1Y 82.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 7.7 + 8.7 + 13 = 51.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Trulieve Cannabis Corp.TRLV | 50.1/100Mixed-positive evidence64% evidence | FADING | 16.3/35 Revenue -1.4% · PAT — · OPM change 0.6 pp 62% evidence | 11.7/25 ROCE 5.6% · OPM 12.4% 76% evidence | 11.5/20 P/E -13.3× · PEG — 15% evidence | 10.6/20 RS sector 1% · RS bench 3.3% · 1Y 55.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 11.7 + 11.5 + 10.6 = 50.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12ANI Pharmaceuticals, Inc.ANIP | 48.8/100Mixed-negative evidence64% evidence | ASLEEP | 22.5/35 Revenue 36.9% · PAT — · OPM change 3.1 pp 62% evidence | 11.4/25 ROCE 3.4% · OPM 16.4% 76% evidence | 10.6/20 P/E 19.5× · PEG — 15% evidence | 4.3/20 RS sector -16.5% · RS bench -14.4% · 1Y -2.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 11.4 + 10.6 + 4.3 = 48.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Alkermes plcALKS | 48.4/100Thin evidence · provisional58% evidence | LEADER | 12.4/35 Revenue — · PAT — · OPM change -16.8 pp 45% evidence | 8.3/25 ROCE 0.7% · OPM -12.3% 76% evidence | 8.9/20 P/E 132.8× · PEG — 15% evidence | 18.8/20 RS sector 26.8% · RS bench 29.3% · 1Y 86%12 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 8.3 + 8.9 + 18.8 = 48.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Teva Pharmaceutical Industries LimitedTEVA | 47.3/100Thin evidence · provisional58% evidence | ASLEEP | 16.5/35 Revenue — · PAT — · OPM change 4.2 pp 45% evidence | 9.3/25 ROCE -0.9% · OPM 33.7% 76% evidence | 9.5/20 P/E 56.5× · PEG — 15% evidence | 12.0/20 RS sector 6.2% · RS bench 8.1% · 1Y 110.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 9.3 + 9.5 + 12 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Zoetis Inc.ZTS | 45.8/100Mixed-negative evidence81% evidence | BASING | 15.2/35 Revenue 2.6% · PAT 5.8% · OPM change -1.5 pp 83% evidence | 17.1/25 ROCE 6.7% · OPM 35.4% 76% evidence | 8.9/20 P/E 19.6× · PEG 2.03 65% evidence | 4.6/20 RS sector -43.3% · RS bench -41.9% · 1Y -48.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 17.1 + 8.9 + 4.6 = 45.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Bausch Health Companies Inc.BHC | 44.9/100Thin evidence · provisional58% evidence | TURNING | 16.0/35 Revenue — · PAT — · OPM change -49.8 pp 45% evidence | 8.9/25 ROCE 3.5% · OPM -37.6% 76% evidence | 11.0/20 P/E 16.5× · PEG — 15% evidence | 9.0/20 RS sector -7.7% · RS bench -5.4% · 1Y 12%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16 + 8.9 + 11 + 9 = 44.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Elanco Animal Health IncorporatedELAN | 43.3/100Mixed-negative evidence71% evidence | TURNING | 15.9/35 Revenue 10.5% · PAT -164.9% · OPM change 2.1 pp 83% evidence | 8.8/25 ROCE 1.2% · OPM 10.5% 76% evidence | 8.5/20 P/E 335.7× · PEG — 15% evidence | 10.1/20 RS sector -0.5% · RS bench 1.5% · 1Y 53.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 8.8 + 8.5 + 10.1 = 43.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18United Therapeutics Corporationthis pageUTHR | 42.7/100Mixed-negative evidence81% evidence | ASLEEP | 15.0/35 Revenue 5.9% · PAT 6.5% · OPM change -6.5 pp 83% evidence | 16.5/25 ROCE 5% · OPM 41.7% 76% evidence | 6.3/20 P/E 21.9× · PEG 2.7 65% evidence | 4.9/20 RS sector -6.7% · RS bench -4.8% · 1Y 72.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 16.5 + 6.3 + 4.9 = 42.7 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 19Prestige Consumer Healthcare Inc.PBH | 42.6/100Mixed-negative evidence71% evidence | BASING | 11.6/35 Revenue -4.3% · PAT -11.2% · OPM change -3 pp 83% evidence | 13.5/25 ROCE 2.3% · OPM 26.8% 76% evidence | 11.1/20 P/E 15.2× · PEG — 15% evidence | 6.4/20 RS sector -22.9% · RS bench -21.1% · 1Y -20.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.6 + 13.5 + 11.1 + 6.4 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Supernus Pharmaceuticals, Inc.SUPN | 40.7/100Mixed-negative evidence64% evidence | ASLEEP | 20.1/35 Revenue 16.3% · PAT -147.5% · OPM change 2.8 pp 62% evidence | 7.6/25 ROCE -0.8% · OPM -4% 76% evidence | 9.9/20 P/E 27.4× · PEG — 15% evidence | 3.1/20 RS sector -21.5% · RS bench -19.7% · 1Y 4.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 7.6 + 9.9 + 3.1 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21BioCryst Pharmaceuticals, Inc.BCRX | 37.2/100Thin evidence · provisional53% evidence | TURNING | 12.0/35 Revenue — · PAT — · OPM change -463.2 pp 32% evidence | 3.3/25 ROCE -230.1% · OPM -448.6% 76% evidence | 11.3/20 P/E 6.4× · PEG — 15% evidence | 10.6/20 RS sector -2.8% · RS bench -0.7% · 1Y 8.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 3.3 + 11.3 + 10.6 = 37.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Hims & Hers Health, Inc.HIMS | 34.5/100Adverse evidence71% evidence | TURNING | 11.2/35 Revenue 32.8% · PAT -107.3% · OPM change -22.8 pp 83% evidence | 5.7/25 ROCE -6.9% · OPM -12.9% 76% evidence | 9.4/20 P/E 63.7× · PEG — 15% evidence | 8.2/20 RS sector -17.4% · RS bench -14.8% · 1Y -38.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 5.7 + 9.4 + 8.2 = 34.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Harrow, Inc.HROW | 34.4/100Thin evidence · provisional55% evidence | ASLEEP | 13.5/35 Revenue 26.3% · PAT — · OPM change -26.5 pp 62% evidence | 4.5/25 ROCE -8.7% · OPM -50% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.4/20 RS sector -14.8% · RS bench -12.9% · 1Y 15.7%5 of 12 weeks ahead 70% evidence |
| Exact sum: 13.5 + 4.5 + 10 + 6.4 = 34.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24AlvotechALVO | 31.2/100Adverse evidence65% evidence | TURNING | 9.6/35 Revenue -4.4% · PAT -183.5% · OPM change 1.1 pp 83% evidence | 8.0/25 ROCE 0.9% · OPM 9.1% 76% evidence | 9.6/20 P/E 51.3× · PEG — 15% evidence | 4.0/20 RS sector -35.5% · RS bench -33.4% · 1Y -54.6%3 of 12 weeks ahead 70% evidence |
| Exact sum: 9.6 + 8 + 9.6 + 4 = 31.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Perrigo Company plcPRGO | 27.0/100Thin evidence · provisional55% evidence | BASING | 8.3/35 Revenue -3.6% · PAT — · OPM change -42.9 pp 62% evidence | 5.0/25 ROCE -4.8% · OPM -38.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.7/20 RS sector -35.5% · RS bench -33.6% · 1Y -52.2%1 of 12 weeks ahead 70% evidence |
| Exact sum: 8.3 + 5 + 10 + 3.7 = 27 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Amylyx Pharmaceuticals, Inc.AMLX | 52.7/100Thin evidence · provisional43% evidence | TURNING | 17.3/35 Revenue — · PAT — · OPM change 6111.6 pp 13% evidence | 6.0/25 ROCE -18.3% · OPM — 61% evidence | 10.4/20 P/E 21× · PEG — 15% evidence | 19.0/20 RS sector 34.5% · RS bench 37.1% · 1Y 186.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 6 + 10.4 + 19 = 52.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27HUTCHMED (China) LimitedHCM | 38.1/100Thin evidence · provisional43% evidence | BASING | 17.3/35 Revenue — · PAT — · OPM change — 12% evidence | 8.2/25 ROCE 0% · OPM — 61% evidence | 9.0/20 P/E 107.6× · PEG — 15% evidence | 3.6/20 RS sector -27.8% · RS bench -26% · 1Y -22.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 8.2 + 9 + 3.6 = 38.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Regencell Bioscience Holdings LimitedRGC | 30.4/100Thin evidence · provisional40% evidence | BASING | 13.4/35 Revenue — · PAT — · OPM change — 24% evidence | 7.0/25 ROCE -60.5% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 0.0/20 RS sector -72.7% · RS bench -72.3% · 1Y -56.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.4 + 7 + 10 + 0 = 30.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is United Therapeutics Corporation's stock price today?
United Therapeutics Corporation trades at $519, +76.3% over the past year. The company is valued at $22.0 B. The stock sits at 75% of its 52-week range of $305–$588, +0.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 36 weeks in. — as of 5 August 2026.
What were United Therapeutics Corporation's latest quarterly results?
United Therapeutics Corporation reported revenue of $0.8 B and net profit of $0.3 B for the Mar 26 quarter. Revenue fell 1.3% and profit fell 15.6% year on year. Earnings per share were $5.82. The operating margin was 42.3%, 5.8 pp lower than a year earlier. — as of 5 August 2026.
What is United Therapeutics Corporation's revenue?
United Therapeutics Corporation reported revenue of $0.8 B in the Mar 26 quarter, −1.3% year on year. For the full FY25 fiscal year, revenue was $3.2 B (+10.4%). Over the last 4 years revenue compounded at 17.1% a year. — as of 5 August 2026.
What is United Therapeutics Corporation's profit?
United Therapeutics Corporation earned $0.3 B of net profit in the Mar 26 quarter, −15.6% year on year. Full-year FY25 profit was $1.3 B. The operating margin ran 42.3% in the latest quarter. — as of 5 August 2026.
What is United Therapeutics Corporation's market cap?
United Therapeutics Corporation's market capitalisation is $22.0 B at a stock price of $519. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is United Therapeutics Corporation's P/E ratio?
United Therapeutics Corporation trades at a P/E of 19.2×, at the 91st percentile of its own 4-year range, against a long-run median of 15.2×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does United Therapeutics Corporation pay a dividend?
No — United Therapeutics Corporation has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is United Therapeutics Corporation overvalued?
On its own history, United Therapeutics Corporation looks expensive against its own history: its P/E of 19.2× sits at the 91st percentile of its 4-year range (long-run median 15.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is United Therapeutics Corporation growing?
Not right now — United Therapeutics Corporation's latest numbers are shrinking: latest-quarter revenue −1.3% year on year, profit −15.6%, and the margin −5.8 pp at 42.3%. The 4-year compound rates are 17.1% (revenue) and 29.0% (profit). The earnings engine currently reads: deteriorating — as of 5 August 2026.
How is United Therapeutics Corporation performing?
United Therapeutics Corporation is in a confirmed uptrend, 36 weeks in. Its latest quarter's revenue fell 1.3% and profit fell 15.6% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is United Therapeutics Corporation in?
Topping out — revenue and EPS growth have decelerated hard (revenue growth +24.4% at its peak → +6.0% latest) while ROCE still reads 21.9%. The read comes from the last 12 quarters of growth (revenue growth +6.0% latest, profit growth +5.8% latest, eps growth +8.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is United Therapeutics Corporation in an uptrend?
Yes — the price is in a confirmed uptrend (week 36 of stage 2), trading +0.7% versus its 200-day average and at 75% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is United Therapeutics Corporation beating the market?
Not lately — on a trailing-13-week view United Therapeutics Corporation is currently behind the S&P 500 (9 weeks and counting; last ahead the week of 2026-06-05), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +367% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.
Will United Therapeutics Corporation's stock price go up?
This page publishes no price forecast for United Therapeutics Corporation. What it measures instead: the stock price is $519, the price is in a confirmed uptrend 36 weeks in. Its P/E of 19.2× sits at the 91st percentile of its own 4-year range. — as of 5 August 2026.
Is the market betting against United Therapeutics Corporation?
Somewhat — short interest is 5.4% of United Therapeutics Corporation's tradable float, about 3.8 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
What is United Therapeutics Corporation's capex?
United Therapeutics Corporation spent $1.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.5 B. — as of 5 August 2026.
What is United Therapeutics Corporation's cash flow?
United Therapeutics Corporation generated $1.6 B of operating cash flow in FY25 and $1.0 B of free cash flow after $0.5 B of capital spending. Reported profit that year was $1.3 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is United Therapeutics Corporation's profit real cash?
Yes — over the last 3 fiscal years, 110% of United Therapeutics Corporation's reported profit arrived as operating cash. In FY25, operating cash was $1.6 B against reported profit of $1.3 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is United Therapeutics Corporation?
On the balance sheet, the Z-score reads 16.45 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is United Therapeutics Corporation in its business cycle?
United Therapeutics Corporation's FY25 operating margin was 46.9%, against a 5-year band of 33.1%–50.6%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 42.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the United Therapeutics Corporation story?
The sharpest disagreement: the price moved +76.3% in a year while annual EPS moved +13.1% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is United Therapeutics Corporation a stock worth studying right now?
This is not investment advice. The machine read: United Therapeutics Corporation's price has outrun its earnings. +76.3% in a year against EPS +13.1% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.